Report: N.J. Doctor Tipped Martoma

Sep 6 2013 | 11:43am ET

A prominent New Jersey Alzheimer's disease doctor passed confidential information to a former SAC Capital Advisors portfolio manager, according to published reports.

Joel Ross is the man identified as "Doctor-2" in the revised indictment against Mathew Martoma, unsealed late last month. Unlike Martoma's other alleged source for tips about Alzheimer's drug trials, Ross has not been accused of any wrongdoing.

Ross is the founder of the Memory Enhancement Center in Eatontown, N.J., a clinical professor at the Mt. Sinai School of Medicine and a proponent of the use of experimental medicines to treat Alzheimer's. As with Sidney Gilman, the former University of Michigan medical professor who has admitted to passing Martoma tips, Martoma met Ross through an expert-networking firm which was not indentified.

And as with Gilman, Martoma's alleged primary interest with Ross was bapineuzumab, an Alzheimer's drug being developed by Elan Corp. and Wyeth LLC. Martoma is accused of illegally-trading shares of those company, earning or saving SAC a combined $276 million; the allegations are also at the heart of the criminal insider-trading case against SAC.

According to the indictment, Ross gave Martoma confidential information about drug trials, including those into bapineuzumab. The two men also met after Ross was briefed on those trial results.

In exchange, the indictment alleges, Martoma "would assist Doctor-2 in obtaining additional clinical trial business." Ross' identity was first reported by The Wall Street Journal.

Martoma has pleaded not guilty and refused to cooperate with prosecutors; he is set to face trial beginning Nov. 4.


In Depth

Q&A: Open Season For Closed-End Funds

Aug 29 2014 | 10:00am ET

When Maury Fertig and Bob Huffman, former Salomon Brothers coworkers, launched...

Lifestyle

Och Funds Women In Finance Initiative At U-M

Aug 28 2014 | 3:01pm ET

Och-Ziff Capital founder Daniel Och and his wife have made a "generous donation"...

Guest Contributor

Looking Ahead: What’s In Store For Managed Futures?

Aug 22 2014 | 12:52pm ET

The last five years were phenomenal for investors in equity indices. Will the next...

 

Editor's Note

    Get A Sneak Peak Of The Alpha Pages

    Aug 25 2014 | 11:21am ET

    As many of you know, FINalternatives was recently acquired by the owners of Futures magazine, a firm called The Alpha Pages LLC. Today marks the soft-launch of a new sister site for both publications. As its name suggests, The Alpha Pages will cover all types of alternative investments, going far beyond the more well-known ones such as hedge funds and private equity. Read more…

 

Futures Magazine

July/August 2014 Cover

The time was right

Commodities/Futures magazine launched at the precipice of a revolution in the futures industry—really a revolution in the idea of risk management—that would move it from a small niche industry to ...

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.